Log in
Enquire now
‌

Margetuximab Expanded Access Program

OverviewStructured DataIssuesContributors
Is a
‌
Clinical study
0
Last Updated
February 22, 2022
0
Trial Sponsor
MacroGenics
MacroGenics
0
NCT Number
NCT03133988
0
Official Name
An Expanded Access Program Providing Margetuximab in the Treatment of HER2+ Metastatic Breast Cancer in Single, Individually-approved Patients
0
Official Website
clinicaltrials.gov/study...133988
0

Find more entities like Margetuximab Expanded Access Program

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.